Posted by Michael Wonder on 14 Jan 2019
SMC - January 2019 decisions
14 January 2019 - A medicine used to treat advanced breast cancer has today been accepted by the SMC for use in NHSScotland.
Pertuzumab (Perjeta) can be used for the treatment of HER2 positive metastatic breast cancer or locally recurrent unresectable breast cancer.
Tofacitinib (Xeljanz) was accepted for the treatment of psoriatic arthritis, a painful and debilitating condition which causes red scaly patches on the skin and inflammation of the joints.
Ertugliflozin (Steglatro) was accepted for the treatment of type 2 diabetes as part of a package of treatment which includes diet and exercise to improve glycaemic control. Ertugliflozin offers patients with the condition another treatment option.
Semaglutide (Ozempic) was also accepted for the treatment of type 2 diabetes alongside a diet and exercise regime.
